Buy BPC-157 UK | HPLC-Verified | COA Per Batch

BPC-157 Peptide | Buy BPC-157 UK | Research Use Only

BPC-157 — also known as Body Protection Compound 157, Stable Gastric Pentadecapeptide BPC 157, and PL-10 — is a synthetic 15-amino acid peptide (GEPPPGKPADDAGLV, MW 1,419 Da) derived from a partial sequence of the endogenous body protection compound first isolated from human gastric juice, with no sequence homology to any other known peptide, that in pre-clinical research demonstrates a uniquely broad tissue-protective and repair-promoting profile spanning tendon, ligament, muscle, bone, and gastrointestinal tissue — acting through a coordinated network of angiogenic, cytoprotective, and fibroblast-signalling mechanisms including VEGFR2/Akt/eNOS, GHR/JAK2, and HO-1 antioxidant pathways — making it the most extensively studied gastric-derived peptide in pre-clinical tissue repair and cytoprotection research. Buy BPC-157 in the UK from Peptides Lab UK with >99% HPLC-verified purity, batch-specific COA, and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in lyophilised format for controlled laboratory research. Each batch is independently verified for purity. This compound is handled strictly in pre-clinical settings with no applications in human or veterinary medicine.

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a stable synthetic pentadecapeptide — a chain of exactly 15 amino acids — originally identified and isolated from human gastric juice by Dr. Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. It represents the biologically active fragment of the larger endogenous Body Protection Compound (BPC, MW ~40,000 Da), the smallest sequence retaining BPC’s full biological activity profile.

What makes BPC-157 distinctive among research peptides is a combination of three properties rarely found together: it has no sequence homology to any other known peptide, it is completely stable in human gastric acid for at least 24 hours (unlike most growth factors and peptide analogues, which are rapidly degraded), and it remains active across an exceptionally broad effective dose range — from nanogram to microgram per kilogram bodyweight in pre-clinical models — without any known toxic dose having been established in animal studies to date.

Endogenously, BPC plays a role in maintaining gastric mucosal integrity and homeostasis. In exogenous research applications, the synthetic BPC-157 fragment has been evaluated across tissue types spanning the entire musculoskeletal system, gastrointestinal tract, liver, pancreas, cardiovascular system, and central nervous system — producing consistently positive results across an unusually wide range of injury and dysfunction models.

Also Known As

• Body Protection Compound 157
• Stable Gastric Pentadecapeptide BPC 157
• PL-10 / PLD-116 / PL 14736 (clinical trial designations)
• Bepecin
• GEPPPGKPADDAGLV

How Does BPC-157 Work?

BPC-157’s mechanism of action is multifaceted and not fully characterised in all tissue contexts. The current evidence base points to several overlapping molecular pathways operating in parallel:

VEGFR2/Akt/eNOS — Angiogenic Signalling

A primary mechanistic axis involves upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), leading to activation of the Akt/eNOS (endothelial nitric oxide synthase) downstream pathway. This drives de novo blood vessel formation — angiogenesis — into injured tissue, which is a prerequisite for sustained repair and regeneration. BPC-157’s angiogenic response has been described as more potent and consistent than standard angiogenic growth factors in comparative studies, and — critically — it functions without requiring special delivery systems or carriers, a significant limitation of most conventional growth factors.

Growth Hormone Receptor Upregulation — GHR/JAK2 Pathway

Research confirmed that BPC-157 dose- and time-dependently increases the expression of the growth hormone receptor (GHR) in tendon fibroblasts at both the mRNA and protein level. This GHR upregulation sensitises local cells to circulating GH, potentiating GH-induced JAK2/STAT signalling and stimulating collagen matrix synthesis, IGF-1 production, and fibroblast proliferation — providing a mechanism through which BPC-157 engages the GH/IGF-1 axis at the tissue level without altering systemic GH secretion.

HO-1 Antioxidant and Cytoprotective Pathway

BPC-157 activates haem oxygenase-1 (HO-1), a key intracellular antioxidant and cytoprotective enzyme, which modulates oxidative stress, reduces lipid peroxidation, and protects cells from HNE (4-hydroxynonenal)-mediated growth inhibition. This HO-1-dependent cytoprotective mechanism may explain much of BPC-157’s observed ability to protect cells against ischaemia-reperfusion injury and oxidative damage across multiple tissue types simultaneously.

Tendon Fibroblast Biology — Outgrowth, Migration, and Survival

In tendon-specific research, BPC-157 significantly accelerates the outgrowth of tendon explants and markedly increases in vitro migration of tendon fibroblasts in a dose-dependent manner. It does not directly stimulate fibroblast proliferation under normal culture conditions, but substantially increases fibroblast survival under hydrogen peroxide-induced oxidative stress — acting as a cytoprotective enhancer of the endogenous repair response rather than a direct mitogenic agent. BPC-157 also antagonises 4-hydroxynonenal (HNE), reversing HNE’s growth-inhibiting effect on cultured tendocytes into growth stimulation.

Nitric Oxide Signalling and Vascular Recruitment

BPC-157 engages the nitric oxide (NO) pathway both through eNOS activation downstream of VEGFR2/Akt and through direct modulation of NO-dependent vascular tone and permeability. Vascular recruitment — the organised attraction of new blood vessel ingrowth into healing tissue — is considered a central mechanism across BPC-157’s cross-tissue cytoprotective effects and is described as a defining feature distinguishing it from other growth factors in the healing biology literature.

FAK-Paxillin Pathway and Cell Motility

BPC-157 has been shown to activate the focal adhesion kinase (FAK)-paxillin signalling pathway, which governs cell motility, migration, and adhesion to the extracellular matrix. This mechanism underpins its fibroblast migration-promoting effects and helps explain its capacity to accelerate tissue repair at a cellular motility level independent of proliferation.

Gastrointestinal Cytoprotection

In its original gastric biology context, BPC-157 promotes mucosal integrity through prostaglandin-independent mechanisms, modulates enteric neuron and glial cell activity, counteracts NSAID-induced intestinal permeability, and demonstrates organoprotective activity across the alimentary canal — from oesophagus to colon — in a range of injury models including ethanol, aspirin, and restraint stress-induced lesions.

Neurotransmitter Modulation

BPC-157 has demonstrated modulatory effects on serotonergic, dopaminergic, and GABAergic neurotransmitter systems in CNS research models — including an anti-serotonin syndrome profile and modulation of dopamine system activity — expanding its research utility beyond peripheral tissue into neurobiological applications.

What Does BPC-157 Peptide Do in Research?

In laboratory and pre-clinical settings, BPC-157 has been studied across a broader range of tissue and system models than almost any other single research peptide. Applications include:

• Tendon repair biology — Achilles tendon transection models, fibroblast outgrowth and migration, collagen synthesis, biomechanical load-to-failure restoration
• Ligament healing — medial collateral and anterior cruciate ligament injury models, fibroblast recruitment, and collagen organisation
• Skeletal muscle repair — muscle crush, transection, and degloving injury models, satellite cell activity, and functional research applications
• Bone healing — fracture models, segmental bone defect, pseudoarthrosis research, and osteogenic effects
• Gastric mucosal biology — cytoprotection, ulcer healing, gut permeability, ethanol and NSAID injury models
• Inflammatory bowel disease models — colitis, short bowel syndrome, and intestinal anastomosis healing
• Liver and pancreas research — hepatoprotection, acute hepatic injury, and pancreatic lesion models
• Angiogenesis research — VEGFR2/Akt/eNOS pathway, vascular recruitment, and neovascularisation
• GHR/JAK2 pathway biology — growth hormone receptor upregulation, collagen matrix synthesis, and IGF-1 axis sensitisation
• HO-1 antioxidant biology — cytoprotection, oxidative stress modulation, and ischaemia-reperfusion protection
• FAK-paxillin cell motility research — fibroblast migration, cell adhesion, and matrix remodelling
• Cardiovascular models — fistula healing, endothelium protection, and cardiac arrhythmia models
• CNS and neuroprotection research — serotonin syndrome models, dopaminergic modulation, neuroinflammation
• Corneal ulcer and wound healing — ocular tissue repair and corneal neovascularisation models
• Anti-inflammatory research — IL-6, TNF-α modulation, and inflammatory cascade attenuation
• NSAID toxicity counteraction — gut permeability protection and gastric mucosal rescue models
• Cancer cachexia models — body weight restoration and IL-6/TNF-α reduction in C26 adenocarcinoma mouse models
• Comparative growth factor pharmacology — BPC-157 vs TGF-β, EGF, VEGF, GDFs in tissue healing context

What Do Studies Say About BPC-157?

The Achilles Tendon Transection Model — Foundational Evidence

The Sikiric laboratory’s Achilles tendon transection research established the foundational tissue-repair evidence base for BPC-157. Treatment with BPC-157 at both microgram and nanogram doses produced full biomechanical research applications — including increased load of failure, load of failure per area, and Young’s modulus of elasticity — alongside functional research applications, superior fibroblast and collagen formation, and restoration of full tendon integrity. Critically, this was achieved without requiring any carrier system, unlike TGF-β and other growth factors that require special delivery mechanisms.

Tendon Outgrowth, Fibroblast Migration, and Cell Survival

The 2010 study by Chang et al. published in the Journal of Applied Physiology confirmed that BPC-157 significantly accelerated outgrowth of Achilles tendon explants, markedly increased in vitro tendon fibroblast migration in a dose-dependent manner, and substantially increased fibroblast survival under H₂O₂-induced oxidative stress — establishing a three-part cellular mechanism (outgrowth, migration, survival) that distinguishes BPC-157’s tendon repair profile from direct mitogenic agents.

GHR Upregulation in Tendon Fibroblasts

The 2018 study by Chang et al. published in Frontiers in Physiology confirmed that BPC-157 dose- and time-dependently increased GHR expression in isolated rat Achilles tendon fibroblasts at both mRNA and protein level, and that GH added to BPC-157-treated fibroblasts produced significant, dose-dependent increases in cell proliferation — establishing GHR upregulation as a specific molecular mechanism through which BPC-157 enhances local tissue sensitivity to growth hormone signalling.

Systematic Review — Orthopaedic Sports Medicine (2025)

The 2025 systematic review by Vasireddi, Hahamyan et al. in Orthopaedic Journal of Sports Medicine — reviewing the complete BPC-157 musculoskeletal literature to June 2024 — confirmed pre-clinical evidence of improved structural, biomechanical, and functional research applications across fracture, muscle, tendon, and ligamentous injury models. The review characterised the pharmacokinetic profile (hepatic metabolism, short half-life <30 minutes, urinary excretion, detection window up to 4 days by mass spectrometry) and confirmed that no adverse events were reported in pre-clinical models. The review also identified the gap in human clinical evidence as the primary limitation of the current BPC-157 literature, with only one small uncontrolled clinical case series published in a human population.

Gastric Cytoprotection and Organoprotection

The foundational 1993 Sikiric et al. overview in the Journal of Physiology-Paris established the stomach-stress-organoprotection conceptual framework underpinning BPC-157’s mechanisms across organ systems — positioning gastric BPC as the parent compound and BPC-157 as the active fragment mediating cytoprotective, anti-ulcer, and organoprotective effects across species and tissue types.

Multifunctionality Review — 2025

The 2025 review by Ziaja et al. in Pharmaceuticals synthesised the full biological activity literature for BPC-157, confirming its pleiotropic beneficial profile across GI, musculoskeletal, cardiovascular, and CNS models, characterising its mechanism network, and noting that its safety profile is among the most favourable of any synthetic research peptide studied to date — with no toxic dose established in animal studies and no LD₁ reported.

Key Cited Studies

• Sikiric P et al. (1993) — A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(6):313–327. PMID: 8298587
• Staresinic M et al. (2003) — Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 21(6):976–983. DOI: 10.1016/S0736-0266(03)00110-4. PMID: 14554207
• Chang CH et al. (2011) — The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 110(3):774–780. DOI: 10.1152/japplphysiol.00945.2010. PMID: 21030672
• Chang CH et al. (2018) — Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Front Physiol 9:1717. DOI: 10.3389/fphys.2018.01717. PMC6290068
• Borrelli F et al. (2019) — Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 377(2):153–159. DOI: 10.1007/s00441-019-03016-8. PMID: 30929094
• Vasireddi N et al. (2025) — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. Orthop J Sports Med 13(7). DOI: 10.1177/15563316251355551
• Ziaja M et al. (2025) — Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals 18(2):185. DOI: 10.3390/ph18020185

BPC-157 vs Other Tissue Repair Peptides in Research

Feature	BPC-157	TB-500 (Thymosin β4)	GHK-Cu	KPV
Origin	Human gastric juice — partial BPC sequence	Thymus — thymosin β4 fragment	Copper-binding tripeptide	α-MSH C-terminal tripeptide
Primary Mechanism	Multi-pathway: VEGFR2/Akt/eNOS, GHR/JAK2, HO-1, FAK-paxillin	Actin sequestration, VEGF, anti-inflammatory	Collagen synthesis, angiogenesis, MMP modulation	Melanocortin receptor — anti-inflammatory
Angiogenesis	Yes — VEGFR2/eNOS primary mechanism	Yes — VEGF upregulation	Yes — capillary formation	Limited direct evidence
Tendon/Ligament Research	Extensive — outgrowth, migration, biomechanical research applications	Yes — actin regulation, fibroblast recruitment	Moderate	Limited
GI Cytoprotection	Extensive — primary research context	Limited	Limited	Anti-inflammatory models
CNS/Neuroprotective Research	Yes — serotonergic, dopaminergic, neuroinflammation	Limited	Yes — nerve growth models	Yes — neuroinflammation
GHR Upregulation	Yes — confirmed in tendon fibroblasts	No	No	No
Stability in Gastric Acid	Yes — resistant for ≥24 hours	No	High (peptide stability)	High
Carrier Required	No — active without delivery system	No	No	No
Effective Dose Range	ng/kg to μg/kg	μg/kg to mg/kg	μg/kg to mg/kg (topical and systemic)	μg range
WADA Status	Prohibited (sports)	Prohibited (sports)	Not listed	Not listed
Best Research Use	Musculoskeletal repair, GI cytoprotection, broad tissue biology	Actin-mediated repair, cardiac and vascular models	Skin and wound healing, collagen biology	GI inflammation, melanocortin research

Quality & Purity Assurance

Every batch of BPC-157 from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy BPC-157 UK — Product Specifications

Property	Detail
Full Name	BPC-157 / Body Protection Compound 157
Also Known As	Stable Gastric Pentadecapeptide BPC 157, PL-10, Bepecin, GEPPPGKPADDAGLV
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Amino Acids	15 (pentadecapeptide)
Molecular Weight	1,419.5 Da
Molecular Formula	C₆₂H₁₀₁N₁₅O₂₂
Effective Dose Range	ng/kg to μg/kg (pre-clinical models)
Purity	>99% (HPLC verified)
Form	Lyophilised powder
Storage	Store dry at -20°C; protect from light
Solubility	Sterile water, bacteriostatic water, or 0.9% saline; highly water-soluble at pH 7

BPC-157 Research Applications

BPC-157 (Body Protection Compound 157) peptide UK is supplied strictly for the following in vitro and pre-clinical research uses:

• Tendon repair — Achilles tendon transection models, fibroblast outgrowth, migration, survival, and biomechanical research applications
• Ligament and muscle healing — MCL, ACL, and skeletal muscle injury models, collagen organisation and functional restoration
• Bone repair — fracture healing, segmental defect, pseudoarthrosis, and osteogenic effect research
• Gastric and intestinal cytoprotection — mucosal integrity, ulcer healing, gut permeability, and NSAID/ethanol injury models
• VEGFR2/Akt/eNOS angiogenic pathway and vascular recruitment biology
• GHR/JAK2 pathway — growth hormone receptor upregulation and GH/IGF-1 axis sensitisation in connective tissue
• HO-1 antioxidant and cytoprotective pathway research
• FAK-paxillin cell motility, fibroblast migration, and matrix adhesion studies
• Inflammatory bowel disease, colitis, and intestinal anastomosis healing models
• Liver and pancreas injury — hepatoprotection and cytoprotective biology
• Cardiovascular models — endothelium, fistula healing, and arrhythmia research
• CNS and neurobiological research — serotonin syndrome, dopaminergic modulation, neuroinflammation
• Anti-inflammatory research — cytokine modulation (IL-6, TNF-α), inflammatory resolution
• Comparative growth factor pharmacology — BPC-157 vs TGF-β, VEGF, EGF, GDFs
• WADA-prohibited compound detection methodology and anti-doping assay development

Why Buy BPC-157 UK from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier providing research-grade compounds verified by independent HPLC testing. When you buy BPC-157 in the UK from us, you receive:

99% purity, HPLC and MS verified, third-party tested

• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer

All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. BPC-157 (Body Protection Compound 157) is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for use in humans or animals. Clinical trial activity has been registered but human safety data remains limited; all citations on this page refer exclusively to pre-clinical animal studies and peer-reviewed mechanistic research and do not constitute a claim of safety or therapeutic efficacy in humans. BPC-157 is classified as a prohibited substance in competitive sport by multiple professional and collegiate sports organisations. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.